Immediately stop the injection if a patient exhibits any of the following symptoms, including changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. The treating physician should be knowledgeable regarding any pretreatment evaluation and appropriate interventions in the event of intravascular disseminated injection. Prompt intervention by an appropriate medical specialist should be given should these signs or symptoms of intravascular injection occur.
Check out these common questions for more info about Radiesse and what you might expect from treatment.
Calcium hydroxylapatite, or CaHA, is what makes Radiesse unique as an injectable aesthetic treatment. It’s the first and only CaHA portfolio available that provides both immediate, natural-looking results and long-term improvement—a year or more in many patients.1-8
Radiesse (+) injectable implant is also indicated for deep injection (subdermal and/or supraperiosteal) for soft tissue augmentation to improve moderate to severe loss of jawline contour in adults over the age of 21.
As with all transcutaneous procedures, injection of these products carries a risk of infection. Injection in the jawline may temporarily alter jaw function.
Introduction of product into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers, for example inject the product slowly and apply the least amount of pressure necessary. Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis, and damage to underlying facial structures.
CaHA particles form a “scaffold” that stimulates fibroblasts to produce collagen for up to a year and elastin for up to nine months (after only one injection).5-10
Check out these common questions for more info about Radiesse and what you might expect from treatment.
Delayed-onset inflammation near the sitio of injection is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the treatment sitio following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.
Use of RADIESSE® in the dorsum of the hand may result in significant swelling of the dorsum of the hand.
Liftera é uma tecnologia de ultrassom microfocado recomendada para tratamentos estfoiticos de rejuvenescimento facial. Ela oferece resultados a curto e longo prazo, é segura e precisa e serve de modo a liftings faciais e corporais e demais procedimentos.
Tell your health care provider if you are taking blood thinners or medicines that can interfere with the clotting of blood, such as aspirin or warfarin. These medicines might make it more likely that you will experience bruising or liftera bleeding at the injection sitio.
The FDA now requires that specific training on the newly-approved jawline indication for fillers be made available by the manufacturer to providers.
These products are contraindicated for patients with severe allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies; patients with known hypersensitivity to any of the components; and patients with bleeding disorders.